

1 **Title:** Prospective assessment of catheter-associated bacteriuria in nursing home residents:
2 clinical presentation, epidemiology, and colonization dynamics

3

4 **Running title:** Epidemiology of catheter-associated bacteriuria

5

6 **Authors:** Chelsie E. Armbruster^{1#}, Aimee L. Brauer¹, Monica S. Humby¹, Jiahui Shao²,
7 Saptarshi Chakraborty²

8

9 **Affiliations:**

10 ¹Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical
11 Sciences, State University of New York at Buffalo

12

13 ²Department of Biostatistics, School of Public Health and Health Professions, State University of
14 New York at Buffalo

15

16

17 #Corresponding author:

18 Chelsie E. Armbruster: chelsiea@buffalo.edu

19 **Abstract** (251/250 words)

20 Background: Catheterization facilitates continuous bacteriuria, for which the clinical significance
21 remains unclear. This study aimed to determine the clinical presentation, epidemiology, and
22 dynamics of bacteriuria in a cohort of long-term catheterized nursing home residents.

23
24 Methods: Prospective urine culture, urinalysis, chart review, and assessment of signs and
25 symptoms of infection were performed weekly for 19 study participants over 7 months. All
26 bacteria $\geq 10^3$ cfu/ml were cultured, isolated, identified, and tested for susceptibility to select
27 antimicrobials.

28
29 Results: 226 of the 234 urines were polymicrobial (97%), with an average of 4.7 isolates per
30 weekly specimen. 228 urines (97%) exhibited $\geq 10^6$ CFU/ml, 220 (94%) exhibited abnormal
31 urinalysis, 126 (54%) were associated with at least one possible sign or symptom of infection, 82
32 (35%) would potentially meet a standardized definition of CAUTI, but only 3 had a caregiver
33 diagnosis of CAUTI. 286 (30%) of bacterial isolates were resistant to a tested antimicrobial
34 agent, and bacteriuria composition was remarkably stable despite a combined total of 54 catheter
35 changes and 23 weeks of antimicrobial use.

36
37 Conclusions: Bacteriuria composition was largely polymicrobial, including persistent
38 colonization by organisms previously considered to be urine culture contaminants. Neither
39 antimicrobial use nor catheter changes sterilized the urine, at most resulting in transient
40 reductions in bacterial burden followed by new acquisition of resistant isolates. Thus, this patient
41 population exhibits a high prevalence of bacteriuria coupled with potential indicators of
42 infection, necessitating further exploration to identify sensitive markers of true infection.

43

44 Funding: This work was supported by the NIH (R00 DK105205, R01 DK123158, UL1

45 TR001412)

46 **Introduction**

47 Urinary catheter placement in healthcare settings is a common medical procedure utilized
48 in the treatment of 60% of critically ill patients, 20% of those in medical and surgical intensive
49 care units, and 5-22% of residents in long-term care facilities (1-6). This is particularly true in
50 nursing homes, where 12-15% of newly-admitted individuals have an indwelling urinary catheter
51 and 5-10% will have long-term urinary catheter use for indications such as chronic pressure
52 ulcers or wounds, traumatic pelvic injury, neurogenic bladder, and having low overall functional
53 status (4, 7-9). However, long-term urinary catheter use increases the risk of developing
54 symptomatic catheter-associated urinary tract infection (CAUTI) and provides a reservoir for
55 antimicrobial resistant bacteria (8, 10, 11).

56 Urinary catheters facilitate the presence of bacteria in urine (bacteriuria) as they bypass
57 many of the natural defenses of the urinary tract. Bacteria that colonize the periurethral area are
58 typically excluded from the urinary tract by a combination of micturition (the regular passing of
59 urine), the physical barrier provided by intact urothelial cells and mucin, and by innate immune
60 defenses. However, insertion of a catheter damages the urothelial barrier, disrupts normal
61 micturition, and causes retention of a low volume of urine within the bladder, all of which
62 facilitate bacterial growth (12-14). The immune response elicited by the catheter also results in
63 accumulation of host proteins such as fibrinogen, which prime the catheter surface and facilitate
64 bacterial attachment (15-17). The combination of these factors creates a uniquely permissive
65 environment for numerous bacterial species to colonize and potentially establish infection.
66 Indeed, for each day that a urinary catheter is in place, there is a 3-8% incidence of bacteriuria,
67 and long-term catheterization (>28 days) typically results in continuous bacteriuria (1, 18).

68 Catheterization and resulting bacteriuria are associated with numerous adverse outcomes,
69 such as functional decline, increased hospital stays, inappropriate or inadequate antimicrobial
70 treatment, and an overall increase in mortality rate compared to non-catheterized individuals (1,
71 6, 18-23). However, catheter-associated bacteriuria is frequently asymptomatic and can be
72 challenging to distinguish from CAUTI, especially in long-term care settings. Guidelines for
73 diagnosis of CAUTI include the presence of clinical signs and symptoms in addition to a positive
74 urine culture (24-26). For instance, the 2010 clinical care guidelines of the Infectious Diseases
75 Society of America (IDSA) define CAUTI as a positive urine culture ($\geq 10^3$ CFU/ml of ≥ 1
76 bacterial species) combined with signs or symptoms compatible with UTI (fever, rigors, altered
77 mental status, malaise or lethargy with no other identified cause, flank pain, costovertebral
78 tenderness, acute hematuria, or pelvic discomfort) in the absence of an alternate source of
79 infection (1, 27). In the absence of these symptoms, a culture with $\geq 10^5$ CFU/ml of ≥ 1 bacterial
80 species is considered asymptomatic catheter-associated bacteriuria (1). In contrast, the National
81 Health Safety Network (NHSN) surveillance criteria for long-term care facilities define
82 symptomatic CAUTI as having a positive urine culture (no more than 2 species, of which at least
83 one must be a bacterium at $\geq 10^5$ CFU/ml of urine) combined with at least one of the following:
84 a) fever (single temperature $>100^\circ\text{F}$, repeated temperatures $>99^\circ\text{F}$, or an increase of $>2^\circ\text{F}$ over
85 baseline), b) rigors, c) new onset hypotension (<90 systolic or <60 diastolic blood pressure)
86 without an alternate non-infectious cause, d) new onset decline in mental or functional status
87 combined with leukocytosis ($>14,000$ leukocytes/ mm^3) and without an alternate diagnosis, e)
88 new or increased suprapubic tenderness, f) new or increased costovertebral pain or tenderness, h)
89 acute pain, swelling, or tenderness of the testes, epididymis, or prostate, or h) purulent discharge
90 from the catheter insertion site (25, 28).

91 Diagnosis of CAUTI is particularly challenging in older adults, especially those with
92 neurogenic bladder, cognitive impairments, or a high degree of functional dependence. In this
93 population, many signs and symptoms of infection (such as fever and leukocytosis) are
94 infrequent or absent, while others may be subtle or non-specific (29-38). A further confounding
95 issue is the high prevalence of acute mental status change and confusion in this population (31,
96 36, 39), coupled with issues regarding reliable assessment of mental status and non-specific
97 symptoms (40). To reduce inappropriate antimicrobial treatment, development of antimicrobial
98 resistance, and risk of *Clostridioides difficile* infection, the 2019 guidelines of the IDSA strongly
99 recommend against screening for or treating asymptomatic bacteriuria in older, functionally or
100 cognitively impaired adults, especially those residing in long-term care facilities, as well as
101 individuals with indwelling urinary catheters (27). The guidelines further indicate that mental
102 status change and bacteriuria without local genitourinary symptoms or systemic symptoms
103 should not be considered to indicate symptomatic UTI in older, functionally or cognitively
104 impaired adults (27). However, non-specific symptoms, such as change in mental status and
105 confusion, are the most common indications for suspected UTI in nursing home residents and
106 antimicrobial prescription for asymptomatic bacteriuria remains common in this population (31,
107 41).

108 While several studies have reported the epidemiology of bacteriuria in catheterized
109 individuals (1, 2, 31, 42-54), few have conducted a longitudinal assessment of colonization
110 dynamics or included prospective assessment of common indicators of CAUTI. These collective
111 studies have also demonstrated that polymicrobial bacteriuria and CAUTI are common during
112 long-term catheterization, yet few report the full etiology of polymicrobial urine cultures. To
113 address these gaps in knowledge, we conducted a prospective longitudinal assessment of

114 bacteriuria in long-term catheterized nursing home residents from two facilities in western New
115 York. Our study had three primary goals: 1) determine the clinical presentation of catheter-
116 associated bacteriuria and CAUTI in long-term catheterized nursing home residents, 2)
117 determine the epidemiology of catheter-associated bacteriuria and CAUTI, including carriage of
118 antimicrobial resistant bacteria, and 3) determine the impact of disruptions, such as catheter
119 changes and antimicrobial treatment, on colonization dynamics.

120 **Results**

121

122 **Description of Study Population**

123 Target enrollment was 50 nursing home residents with long-term indwelling urinary
124 catheters (≥ 1 year), but the study was ended early due to COVID-19 with 19 participants
125 followed for a maximum of 7 months each. As summarized in Table 1, the majority of study
126 participants were white (79%), male (79%), and had suprapubic catheters (68%). Study
127 participants exhibited a high level of functional dependence for activities of daily living, with an
128 average physical self-maintenance score (PSMS) of 22 on a scale ranging from 6-30 (55). The
129 most common comorbidities were neurogenic bladder (74%), hemiplegia (42%), diabetes (32%),
130 renal disease (32%), multiple sclerosis (26%), and chronic heart failure (26%).

131 Study participants were followed for a total of 260 patient-weeks (13 average, range 1-
132 30), with 9 of the 19 participants completing greater than 12 weeks of follow-up. Including
133 baseline samples, 234 urine cultures were collected during the study (average 12 per participant,
134 range 1-28). Ten participants (53%) had at least one catheter change between weekly follow-up
135 visits, for a combined total of 54 catheter changes (5 average, range 1-12). Notably, 13 catheter
136 changes occurred due to blockage/obstruction, 5 occurred due to accidental removal/dislodging,
137 and the remaining 36 catheter changes were listed as routine care. Four participants (21%)
138 experienced a combined total of 8 caregiver-diagnosed infections during follow-up, 3 of which
139 were CAUTIs. Three participants (16%) had received antibiotics within 30 days prior to their
140 baseline visit, and six participants (32%) received antimicrobial treatment during the course of
141 follow-up for a total of 23 patient-weeks of antimicrobial use, including 2 participants who
142 received antimicrobial treatment for 3 CAUTIs.

143

144 **Epidemiology of Catheter-Associated Bacteriuria**

145 234 urine samples were collected during 260 study visits. Samples could not be obtained
146 at 26 study visits due to absence of the participant on a particular visit or the participant not
147 wanting to be disturbed that day. All urine samples were subjected to semi-quantitative streak
148 plating for isolation of all distinct colony types and biochemical determination to the species
149 level (see Methods), as well as quantitative dilution plating on HardyCHROM UTI agar to
150 determine total colony forming units (CFU) per milliliter of urine. Of the 234 urine cultures, 233
151 (99%) exhibited bacterial growth $>10^3$ CFU/ml, with an average of 5.12×10^6 CFU/ml (range
152 $5.5 \times 10^4 - 6.2 \times 10^6$ CFU/ml). Notably, the only culture-negative urine was obtained from a study
153 participant receiving intravenous antimicrobials for CAUTI with bacteremia.

154 A total of 1,092 bacterial isolates were cultured from 233 urines, of which 623 (57%)
155 were Gram-negative and 469 (43%) were Gram-positive. Select antimicrobial susceptibility was
156 assessed by zone of growth inhibition on Mueller-Hinton agar. All 623 Gram-negative isolates
157 were tested for susceptibility to ciprofloxacin, ceftazidime, ceftazidime with clavulanate, and
158 imipenem, all 168 *S. aureus* isolates were tested for methicillin susceptibility, and all 163 *E.*
159 *faecalis* isolates were tested for vancomycin susceptibility. Of these combined 954 isolates, 286
160 (30%) were resistant to at least one antimicrobial agent and resistant organisms were present in
161 urine specimens from 12 of the 19 participants (63%, Table 2). The most common resistances
162 were ciprofloxacin (171/623 Gram-negative isolates [27%]), methicillin (81/168 *Staphylococcus*
163 *aureus* isolates [48%]), and ceftazidime (37/623 Gram-negative isolates [6%]). Notably, all
164 isolates that were resistant to ceftazidime were also resistant to ceftazidime with clavulanic acid,
165 indicating production of an extended spectrum β -lactamase (ESBL). None of the Gram-negative

166 isolates were resistant to imipenem, and none of the *E. faecalis* isolates were resistant to
167 vancomycin.

168 Antimicrobial resistance was most prevalent for *Proteus mirabilis* (69% of isolates), *S.*
169 *aureus* (48%), *Providencia stuartii* (44%), *Morganella morganii* (37%), *Pseudomonas*
170 *aeruginosa* (29%), and *Escherichia coli* (29%) (Table 2). For most organisms, all sequential
171 isolates from a single participant exhibited the same colony morphology and resistance profile,
172 with the exception of *S. aureus*. Methicillin-resistant *S. aureus* (MRSA) is therefore discussed
173 separately from methicillin-sensitive *S. aureus* (MSSA).

174 The vast majority of culture-positive urines were polymicrobial (226/233, 97%), with an
175 average of 4.7 isolates per weekly urine specimen (range 1-10); 30 (13%) harbored two distinct
176 isolates, 24 (11%) had three isolates, 39 (17%) had four isolates, 52 (23%) had five isolates, 41
177 (18%) had six isolates, 18 (8%) had seven isolates, and 22 (9%) had eight or more distinct
178 isolates. A visualization of the full colonization data for each participant at each weekly visit is
179 provided in Supplemental Figure 1, and longitudinal colonization data from four study
180 participants is displayed in Figure 1 to align bacteriuria composition with urinalysis and sign and
181 symptom data. As displayed in Table 3, the most common organisms at baseline were
182 *Enterococcus faecalis* (14/19 baseline urine specimens, 74%), *P. stuartii* (8/19, 42%), *E. coli*
183 (7/19, 37%), coagulase-negative *Staphylococcus* (7/19, 37%), and *P. mirabilis* 6/19, 32%). When
184 examined across all study visits, 18/19 participants (95%) were colonized by *E. faecalis* during at
185 least one study visit, 11/19 (58%) *P. mirabilis*, 11/19 (58%) coagulase-negative *Staphylococcus*,
186 9/19 (47%) *P. stuartii*, 9/19 (47%) MRSA, 9/19 (47%) MSSA, 8/19/19 (42%) *E. coli*, 8/19
187 (42%) *P. aeruginosa*, 5/19 (26%) *M. morganii*, and 5/19 (26%) *K. pneumoniae*. Thus, the
188 highest weekly prevalence was observed for *E. faecalis* (63%), *P. mirabilis* (45%), *P. stuartii*

189 (43%), and *S. aureus* (33% for methicillin-sensitive isolates and 31% for methicillin-resistant
190 isolates). The most stable and persistent colonizers were *E. faecalis*, *P. mirabilis*, *P. stuartii*, and
191 *E. coli*, while organisms such as *P. aeruginosa*, *Providencia rettgeri*, *Klebsiella pneumoniae*,
192 coagulase-negative *Staphylococcus*, and *Serratia marsescens* tended to exhibit transient
193 colonization. Consistent with the high percentage of polymicrobial urines, the majority of the
194 study participants exhibited polymicrobial bacteriuria during at least one study visit (18/19,
195 95%): 15/19 (79%) exhibited polymicrobial bacteriuria at all weekly visits, 3/19 (16%) mostly
196 had polymicrobial specimens with one or two monomicrobial samples, and one participant only
197 exhibited monomicrobial urine samples (Figure 2).

198 Microbe-microbe interactions during polymicrobial colonization can have profound
199 implications for risk of developing severe disease (56-61). To quantify such interactions, we first
200 computed the number of occurrences for each microbial species (i.e., the total number of
201 participants colonized by that species) at each time point across the entire longitudinal dataset.
202 We then computed Lin's concordance correlation coefficient (62) between the number of
203 occurrences of each microbial pair over the entire longitudinal dataset (Supplemental Table 1).
204 Highly concordant co-colonization partners included *P. mirabilis* with *P. stuartii* (80/233
205 culture-positive urines [34%]; 8/19 participants [42%]), *P. mirabilis* with *M. morgani* (52/233
206 [22%]; 4/19 [21%]), *M. morgani* with *P. stuartii* (63/233 [27%]; 5/19 [26%]), *P. mirabilis* with
207 *E. faecalis* (93/233 [40%]; 9/19 [47%]), and *P. stuartii* with *E. faecalis* (86/233 [37%]; 8/19
208 [42%]). A total of 205 urine samples from all 19 study participants contained at least one of these
209 four organisms; 121 (59%) samples from 11 participants contained at least two of the four
210 concordant organisms, 71 (35%) samples from 7 participants contained at least three, and 50
211 (24%) samples from 4 participants included all four organisms. It is also notable that co-

212 colonization by these species occurred in both men and women, and with both catheter types
213 (Foley *versus* suprapubic).

214

215 **Clinical Presentation of Catheter-Associated Bacteriuria**

216 Potential signs and symptoms of infection were prospectively assessed by a nurse at each
217 study visit, and also collected from participant medical records to determine point prevalence at
218 baseline, weekly prevalence, and incidence (Table 4). Assessment included pain (defined as
219 suprapubic and/or costovertebral pain or tenderness), fever (defined as temperature >99°F),
220 hypotension (defined as <90 systolic or <60 diastolic blood pressure), acute mental status change
221 (defined as altered level of consciousness, inattention, or disorganized thinking in one of two
222 mini-cognitive assessments conducted 30 minutes apart), nausea, lack of appetite, and fatigue.
223 The sign and symptom assessment tool utilized by the study nurses is provided in Supplemental
224 Figure 2. Overall, 16/19 (84%) participants exhibited potential signs and symptoms of infection
225 at 126/260 (48%) study visits. A visualization of the sign and symptom data for each participant
226 at each weekly visit is provided in Supplemental Figure 3, and data aligned to bacteriuria and
227 urinalysis results from four participants are displayed in Figure 1.

228 The most common clinical presentations at baseline were hypotension (3/19, 16%),
229 fatigue (3/19, 16%), and lack of appetite (3/19, 16%). Altered mental status, fatigue, and lack of
230 appetite exhibited the highest weekly prevalence and incidence, while fever, chills, and
231 leukocytosis were absent at baseline, had a low weekly prevalence and incidence, and were
232 typically only present at a single study visit. Lin's concordance correlation coefficients between
233 the number of occurrences of sign and symptom pairs across the entire longitudinal dataset
234 displayed a high degree of concordance between nausea, lack of appetite, fatigue or tiredness,

235 and pain (Supplemental Table 2). Of the 14 participants who completed at least 4 weeks of
236 follow-up, 3 (21%) were asymptomatic for the vast majority of visits, 3 (21%) experienced one
237 or two symptomatic episodes that lasted approximately three weeks (including three of the four
238 individuals who experienced caregiver-diagnosed infections), 4 (29%) experienced frequent
239 multi-week stretches of potential signs or symptoms of infection interspersed with one or two
240 asymptomatic weeks, and 4 (29%) exhibited potential signs or symptoms of infection at every
241 study visit. These data highlight some of the challenges for diagnosing CAUTI in long-term
242 catheterized nursing home residents, including the high prevalence and subjective nature of
243 constitutional signs and symptoms of infection (such as nausea, lack of appetite, and fatigue) in
244 this patient population.

245 Due to the high burden of bacteriuria and possible signs and symptoms of infection in
246 this population, 82/260 (31%) study visits would potentially meet the IDSA CAUTI criteria (1,
247 27). If only new-onset symptoms are considered, this number is reduced to 51/260 (20%). Only 6
248 study visits would meet the more strict NHSN surveillance definition for CAUTI (25, 28) due to
249 the stringent cutoff of ≤ 2 organisms in the urine culture and the requirement that acute mental
250 status change must be accompanied by leukocytosis (which was not prospectively assessed and
251 only reported in the medical records of 3 study participants). Importantly, none of the 3
252 caregiver-diagnosed CAUTIs would meet the NHSN surveillance criteria since all 3 involved >2
253 organisms. However, 2 of the 3 diagnosed CAUTIs involved bacteremia with one of the bacterial
254 species present in urine (Supplemental Table 3), indicating that these cases likely represent true
255 CAUTI. Supplemental Table 3 also demonstrates substantial concordance between the bacterial
256 culture results and sign and symptom analysis conducted by the study team and those reported in
257 the participants' medical records. If urine cultures containing 3 or more organisms are permitted

258 for the NHSN criteria, the number of visits that would meet the NHSN CAUTI surveillance
259 definition increases to 27 and includes all 3 caregiver-diagnosed CAUTIs. Taken together,
260 prospective weekly assessment of possible signs and symptoms of CAUTI revealed that
261 numerous potential indicators of infection are common in nursing home residents with long-term
262 catheters and fluctuate in duration, which may further confound the utility of these indicators for
263 distinguishing CAUTI from asymptomatic bacteriuria in this patient population.

264 All urine samples were also subjected to urinalysis via 10-parameter urine reagent test
265 strip to determine the point prevalence of parameters that are often considered to be suggestive
266 of urinary tract infection, along with weekly prevalence and incidence (Table 5). A visualization
267 of the urinalysis data for each participant at each weekly visit is provided in Supplemental Figure
268 4, and aligned with bacteriuria and symptom data for four participants in Figure 1. The most
269 common urinalysis findings at baseline were a positive result for leukocyte esterase (17/19
270 participants, 89%), nitrites (10/19, 53%) hematuria (8/19, 42%), and proteinuria (5/19, 26%).
271 The highest weekly prevalence was observed for leukocyte esterase, proteinuria, and nitrites.
272 Leukocyte esterase and high pH were highly persistent and typically identified in multiple
273 consecutive urine samples, while hematuria and ketones were more likely to be present at a
274 single study visit. Overall, 226 of the 227 urine specimens tested (99%) had a urinalysis result
275 that could be suggestive of infection in a non-catheterized individual and may therefore influence
276 perception of urine culture results. While this is likely just a reflection of the ubiquitous
277 bacteriuria experienced by this patient population, these data underscore the need for caution
278 when interpreting urinalysis results and possible signs and symptoms of urinary tract infection in
279 nursing home residents with long-term indwelling catheters.

280

281 **Impact of Catheter Changes and Antibiotic use on Colonization Dynamics and Symptom**
282 **Burden**

283 The epidemiology of bacteriuria was remarkably consistent across consecutive study
284 visits, often with only minor or transient perturbations. We therefore sought to determine the
285 impact of catheter changes and antimicrobial use on colonization dynamics for all instances with
286 at least three weeks of post-event follow-up (Table 6). Eight participants with at least 12 weeks
287 of follow-up had an average of 5.75 catheter changes each (range 0-12). Catheter changes
288 resulted in a combined loss of 28 isolates, with an average loss of 3.5 per participant (Table 6).
289 However, 20 of the 28 isolates (71%) were regained within the subsequent 4 weeks, indicating
290 that catheter changes were not effective in reducing bacteriuria long-term. Strikingly, 23 new
291 isolates were acquired after catheter changes, for an average of 2.9 new isolates per participant
292 gained from catheter changes. Altogether, catheter changes resulted in a net increase of 1.9
293 isolates, indicating that changing the catheter was more likely to introduce new organisms than
294 reduce colonization by existing organisms. Furthermore, four participants (50%) acquired at least
295 one new isolate resistant to a tested antimicrobial after a catheter change: 5 of the 23 new
296 acquisitions were resistant organisms (22%), resulting in 28% average incidence of new
297 acquisition of resistant organisms following catheter changes. Importantly, there was no common
298 source of transmission of new resistant organisms among these four participants as two resided at
299 facility A and two resided at facility, and all were from different units on different floors within
300 each facility.

301 In addition to catheter changes, three participants with at least 12 weeks of follow-up
302 each received at least one patient-week of antimicrobial treatment with at least 3 weeks of
303 subsequent follow-up (Table 6). Treatment resulted in a combined loss of 8 isolates, with an

304 average loss of 2.7 colonizing isolates per participant. Similar to catheter changes, 4 of the 8
305 isolates (50%) were regained within the subsequent 3 weeks, and 5 new isolates were acquired
306 (average of 1.7 per participant) resulting in a net increase of 0.3 isolates after antimicrobial
307 treatment. One of the 5 new isolates was resistant to a tested antimicrobial (20%), resulting in a
308 17% average incidence of new acquisition of resistant organisms following treatment.

309 It is also notable that 15/27 (56%) study visits during which the NHSN CAUTI criteria
310 would be met if bacteriuria with ≥ 3 organisms is permitted occurred within 10 days after a
311 catheter change or antibiotic use, including all 3 of the caregiver-diagnosed CAUTIs. To further
312 explore the impact of catheter changes and antibiotic use on colonization dynamics and symptom
313 burden, two multivariate Bayesian multilevel models were used to analyze the entire dataset to
314 determine the contribution of parameters at any given visit to the likelihood of a specific microbe
315 (Supplemental Figure 5) or symptom (Supplemental Figure 6) being present at the following
316 study visit. The Bayesian models coherently address missingness in the data, and provide
317 probabilistic quantification of modeling uncertainties (see Methods for details). For bacterial
318 colonization, the main contributor to colonization by a specific microbe at any given study visit
319 was the presence of that same microbe at the prior study visit, which reflects the overall high
320 degree of stability in colonization. Interestingly, neither antibiotic use nor catheter changes
321 significantly altered the likelihood of colonization by any specific microbe in this analysis,
322 although antibiotic use resulted in a trend towards decreased likelihood of colonization by
323 MSSA, *P. rettgeri*, *P. stuartii*, *M. morgani*, *P. mirabilis*, *E. faecalis*, and miscellaneous PYR-
324 negative Catalase-negative Gram-positive isolates as well as a trend towards increased likelihood
325 of colonization by *P. aeruginosa* and coagulase-negative *Staphylococcus* species. In agreement
326 with our qualitative assessment of the impact of catheter changes and antibiotic treatment on

327 colonization over time (Table 6), neither event significantly reduced the total number of bacterial
328 species present in urine samples from week to week (95% posterior credible intervals for the
329 odds ratios are 0.9994-1.0022 and 0.5546-1.0003 respectively, Figure 2). Similar results were
330 observed for analysis of possible signs and symptoms of infection, with the main contributor to
331 the presence of most symptoms at any given study visit being the presence of that same symptom
332 at the prior study visit, especially for hypotension, pain, fatigue or tiredness, and acute mental
333 status change. Antibiotic use resulted in a slight trend towards increased likelihood of nausea and
334 chills, while catheter changes had no apparent impact in this analysis.

335 **Discussion**

336 CAUTIs are common in nursing home residents with long-term indwelling catheters and
337 the leading cause of antimicrobial prescriptions in this population (63). However, it is estimated
338 that approximately one-third of CAUTIs are misdiagnosed asymptomatic bacteriuria, for which
339 antimicrobial therapy is not considered to be beneficial (64, 65). Part of the discrepancy is due to
340 the challenges of diagnosing CAUTI, especially in a patient population that frequently presents
341 with atypical symptoms. While our sample size was small, our study clearly demonstrates that
342 nursing home residents with long-term catheters routinely have bacteriuria $>10^5$ CFU/ml
343 combined with abnormal urinalysis results and numerous possible signs and symptoms of urinary
344 tract infection, which underscores the difficulties of diagnosing true infection in this population.

345 Interestingly, there were no clear differences in the composition of bacteriuria between
346 weekly asymptomatic cultures, study visits that would meet either the IDSA or NHSN CAUTI
347 criteria, and study visits at which participants had a caregiver diagnosis of CAUTI. It is
348 particularly striking that the organisms present at the time of all three caregiver diagnosed
349 CAUTIs had been persisting in the participants' urine specimens for several weeks prior to
350 symptom onset and diagnosis (see participants G and J in Supplemental Figure 1). Further
351 investigation of urine specimens using metagenomics and proteomics will be necessary to
352 determine if development of signs and symptoms of infection correlates with the presence of
353 specific organisms including those not detected by standard culture techniques such as fungi,
354 anaerobic bacteria, and viruses, or to changes in the host immune response. Assessment of a
355 larger patient population will also be necessary to determine which combinations of factors
356 provide the greatest sensitivity and specificity for CAUTI requiring therapeutic intervention
357 *versus* asymptomatic colonization.

358 Over-testing of urine samples, both by culture and urinalysis, has been demonstrated to
359 have a predominantly negative impact on patient outcomes including inappropriate antimicrobial
360 prescription and increased duration of hospitalization (66-72). For instance, detection of pyuria
361 in preoperative urinalysis was recently demonstrated be associated with prescription of
362 antimicrobials even in the absence of a positive urine culture or urinary symptoms (73).
363 Importantly, pyuria itself was not associated with any negative postoperative outcomes, but the
364 resulting antimicrobial use increased risk of subsequent *Clostridioides difficile* infection without
365 improving any other outcomes (73). This issue is further complicated in catheterized individuals,
366 older adults, and those with neurogenic lower urinary tract dysfunction, for whom pyuria and
367 positive urine cultures are common, and fever, dysuria, urgency, and pain demonstrate minimal
368 sensitivity and specificity for differentiating UTI from asymptomatic bacteriuria (27, 68, 74-79).
369 A recent study identified fever as the primary indication for obtaining a urine culture from
370 catheterized individuals, even when other urinary symptoms were lacking and there were
371 possible alternative explanations of fever (80). Abnormal urinalysis is another common
372 indication for obtaining a urine culture in hospital settings (68), despite lack of other urinary
373 symptoms and IDSA guidelines to the contrary. Considering the almost ubiquitous bacteriuria
374 and abnormal urinalysis results observed in this study, coupled with a high prevalence of non-
375 specific signs and symptoms of possible infection, our data underscore the critical need for
376 discovery of additional indicators of true infection in this patient population.

377 Frequent exposure to antimicrobials has been demonstrated to result in a high carriage
378 rate of antimicrobial resistant organisms in nursing home residents, particularly those with
379 indwelling devices (8, 10, 11). While only 6 of the 19 participants received antimicrobials during
380 the course of the study, 12 participants (63%) were colonized by at least one bacterium that was

381 resistant to a tested antimicrobial, and 26% of the 234 urine cultures contained at least one
382 resistant bacterium. The persistence of antimicrobial resistant isolates was also striking. For
383 instance, of the 9 participants with MRSA bacteriuria, 4 exhibited MRSA for at least 8 weeks
384 despite multiple catheter changes, and similar trends were observed for resistant Gram-negative
385 bacteria.

386 Regarding persistent colonization, our data indicate that bacteriuria remains remarkably
387 stable in individuals with long-term urinary catheters even after numerous catheter changes, and
388 antimicrobial treatment only transiently reduced colonization of some of the organisms. It is
389 alarming that antibiotic use did not sterilize the urine for any of the study participants, with the
390 exception of a single urine sample taken from participant G while they were undergoing several
391 weeks of intravenous antibiotic exposure. While antibiotic use often resulted in an immediate
392 loss of one or two colonizing organisms, the net change in colonization favored an eventual
393 increase back to the same total number of species present prior to treatment, and often included
394 new acquisition of a resistant bacterium. Changing the catheter upon initiation of antimicrobial
395 treatment has been suggested to expand the duration of post-treatment culture-negative
396 bacteriuria (81), but there is no clear improvement of clinical outcomes (82). Catheter insertions
397 can also have a substantial negative impact due to the risk of creating a false passage, bladder
398 perforation, external trauma, and hematuria, in addition to potentially inducing symptomatic
399 CAUTI (71). Thus, our exploratory data suggest that catheter changes in long-term catheterized
400 nursing home residents with asymptomatic bacteriuria may impose a risk of increased acquisition
401 of bacteria as well as new onset of signs and symptoms that are often considered to be indicators
402 of infection without substantially reducing bacterial burden. It is important to note that not all of
403 the reported catheter changes could have been avoided, as 13 of the 54 changes (24%) were due

404 to catheter obstruction or blockage and 5 (9%) were due to accidental removal or dislodging of
405 the catheter. However, the remaining 36 (67%) were reported as routine care and could
406 potentially have been avoided. While further studies are necessary, these preliminary
407 observations provide support for catheter care practices of only changing the catheter when
408 necessary and strictly adhering to stewardship guidelines.

409 The prevalence of polymicrobial bacteriuria during long-term catheterization has been
410 widely reported for decades (1, 2, 50). However, polymicrobial clinical urine specimens are
411 often suspected of harboring periurethral or vaginal microbiota, particularly when they include
412 Gram-positive organisms (83, 84). This has complicated investigation of the clinical significance
413 of polymicrobial bacteriuria and assessment of the contribution of these organisms to
414 pathogenesis. It is therefore notable that prospective assessment of bacteriuria revealed that
415 *Enterococcus faecalis*, *Staphylococcus aureus*, and coagulase-negative *Staphylococcus* are
416 prevalent and persistent constituents of bacteriuria in nursing home residents with long-term
417 indwelling catheters, especially as they may facilitate transient bacteremia, hematogenous
418 seeding of other body sites, and endocarditis (85). In elderly catheterized individuals, ~4% of
419 catheter changes were demonstrated to result in transient bacteremia, including by coagulase-
420 negative *Staphylococcus* species (1, 86). Bacteremia due to *S. aureus* has also been observed in
421 ~7% of patients with *S. aureus* bacteriuria, particularly those of advanced age or residing in
422 nursing homes (87). Furthermore, identification of *S. aureus* bacteriuria \geq 48 hours prior to
423 bacteremia was associated with an increased risk of mortality (87). Further research is necessary
424 to determine if persistent catheter-associated bacteriuria with Gram-positive organisms increases
425 risk of bacteremia and hematogenous seeding of other body sites, and if polymicrobial
426 bacteriuria further modifies risk.

427 Overall, the most frequent and persistent cause of polymicrobial bacteriuria in this study
428 was *E. faecalis* with *P. mirabilis*. The association of these organisms may have important clinical
429 implications, as interactions between *P. mirabilis* and *E. faecalis* increase the likelihood of
430 developing urinary stones and bacteremia in experimental models of CAUTI (17, 60). Ineffective
431 antimicrobial treatment has also been reported to be more common for polymicrobial UTI and
432 those involving *E. faecalis* (23). It may therefore be hypothesized that CAUTI sequelae and
433 mortality may be more common in co-colonized study participants than those who were not co-
434 colonized. While the present study was not sufficiently powered to address this hypothesis, it is
435 worth noting that three study participants developed urinary stones, pyelonephritis, or urosepsis
436 (rows D, G, and J of Supplemental Figure 1); all three were colonized by *P. mirabilis*, and two
437 exhibited co-colonization with *E. faecalis*. All three participants were also co-colonized by
438 *Providencia stuartii*, which has similarly been shown to interact with *P. mirabilis* and enhance
439 risk of urinary stones and bacteremia (17, 88). However, other co-colonized participants did not
440 exhibit infection or sequelae (such as rows A, C, and E), underscoring that these polymicrobial
441 interactions are one of many factors that contribute to the risk of developing severe disease.
442 Further investigation of complex polymicrobial interactions in the catheterized urinary tract are
443 likely to provide new insight into potential decolonization strategies or therapeutics to reduce the
444 risk of progressing from asymptomatic bacteriuria to CAUTI and associated sequelae.

445 The results of this study should be considered in light of several strengths and
446 weaknesses. Main strengths of the study include 1) prospective longitudinal urine culturing
447 rather than collection of a single specimen per participant; 2) prospective assessment of possible
448 signs and symptoms of infection; 3) weekly study visits conducted by the same study personnel;
449 4) weekly urine culturing and antimicrobial susceptibility testing to identify and characterize all

450 isolates prior to any laboratory adaptation and to monitor dynamics of colonization; and 5)
451 enrollment at two nursing facilities. Limitations of the study include the limited sample size and
452 exploratory nature of the study, lack of a control group for assessment of the impact of catheter
453 changes and antibiotic use, low diversity of study participants, limited duration of follow-up for
454 some study participants, inability to conduct assessments for all participants at all study visits,
455 and use of biochemical tests to identify bacterial isolates rather than a more sensitive technology
456 such as matrix assisted laser desorption ionization-time of flight mass spectrometry (MALSI-
457 TOF MS). While our study is exploratory in nature and these limitations preclude more
458 sophisticated analysis of the relationship between catheter changes, antibiotic use, presence of
459 specific organisms, and clinical presentation, this study still represents a significant advance in
460 our understanding of the dynamics and epidemiology of bacteriuria in nursing home residents
461 with long-term urinary catheters. Further investigations of this nature may reveal the host and
462 microbial factors that provide the greatest sensitivity and specificity for CAUTI requiring
463 therapeutic intervention *versus* asymptomatic colonization. If so, this information could help in
464 refining existing tools and determining which course of action should be taken for a given
465 patient, therefore guiding appropriate antimicrobial treatment and possibly reducing acquisition
466 of antimicrobial resistance.

467 **Methods**

468

469 **Ethics statement.** This study was approved by the University at Buffalo Institutional Review
470 Board (STUDY00002526) and complied with the provisions of the Declaration of Helsinki,
471 Good Clinical Practice guidelines, and local laws and regulations. All participants (or approved
472 decision makers) provided written informed consent prior to initiation of investigation, and all
473 participants also assented to being in the study.

474

475 **Study design.** A prospective observational cohort study of asymptomatic catheter-associated
476 bacteriuria was conducted at two nursing homes located in Buffalo, New York between July
477 2019 and March 2020. Study visits occurred at enrollment and weekly thereafter for up to 7
478 months. Each study visit entailed chart review by trained research staff as well as a brief
479 assessment of possible signs and symptoms of infection and collection of a urine specimen by
480 one of three licensed practicing nurses (LPNs) from the Visiting Nurse Association of Western
481 New York. Participants were withdrawn from the study upon indication that they no longer
482 wanted to participate, removal of the indwelling catheter without replacement, transfer to a non-
483 participating facility, or death. All study data and records were managed using REDCap
484 (Research Electronic Data Capture) tools (89, 90), hosted through the University at Buffalo
485 Clinical and Translational Science Institute.

486

487 **Inclusion criteria.** Nursing home residents at either of the two participating facilities were
488 eligible for inclusion if they had an indwelling urinary catheter (Foley or suprapubic) for at least
489 12 months, were at least 21 years of age, were capable of assenting to participation, and

490 informed consent could be obtained from the resident or approved decision maker. Residents
491 receiving end-of-life care were excluded from the study.

492

493 **Data collection from chart review.** Information pertaining to participant demographics, age,
494 weight, gender, comorbidities, functional status, indication for catheterization, duration of
495 indwelling catheter use, history of urinary tract infection, and history of antimicrobial use were
496 obtained from participant medical records by trained research staff on the baseline visit. Chart
497 reviews were also conducted at each weekly study visit to obtain information pertaining
498 suspected infections, hospitalizations, urine culture results, urinalysis results, and antimicrobial
499 prescriptions. Potential signs and symptoms of CAUTI that were recorded include fever (defined
500 as having a single temperature $>100^{\circ}\text{F}$ or repeated temperatures $>99^{\circ}\text{F}$ or $>2^{\circ}\text{F}$ above baseline),
501 suprapubic or costovertebral pain or tenderness, hypotension, chills or rigors, and acute mental
502 status change (defined as a fluctuation in behavior, inattention, disorganized thinking, or an
503 altered level of consciousness compared to baseline) (24, 25).

504 If a study participant was temporarily transferred to a hospital, medical records from the hospital
505 stay were utilized to obtain information pertaining to suspected infections.

506

507 **Assessment of possible signs and symptoms of infection.** At each study visit, an LPN collected
508 vital signs (tympanic temperature and blood pressure) and assessed costovertebral and
509 suprapubic pain or tenderness. The LPN and a study team member also conducted a Delirium
510 Triage Screen (DTS) (91) at the start of each visit and a Brief Confusion Assessment Method
511 (bCAM) (91) assessment at the end of each visit to identify altered mental status (defined as
512 fluctuating altered mental status, including altered level of consciousness, inattention, and

513 disorganized thinking). The LPN and study team member also administered an oral questionnaire
514 at each study visit to determine if the participant had experienced rigors or chills, nausea, lack of
515 appetite, or fatigue since the previous visit. The sign and symptom assessment tool utilized by
516 the study nurses is provided in Supplemental Figure 2.

517

518 **Urine collection.** Urine specimens were collected from the port of the indwelling catheter by an
519 LPN using aseptic technique. Briefly, the catheter tubing was clamped ~12 inches below the
520 latex rubber port and urine was allowed to collect for approximately 30 minutes. The catheter
521 port was then swabbed with an alcohol wipe and allowed to dry for ~30 seconds. The needle of a
522 sterile syringe was then inserted into the port, and urine was withdrawn and transferred into a
523 sterile specimen jar. Urine specimens were placed in an insulated cooler with ice packs and
524 stored therein for no more than 4 hours prior to culturing.

525

526 **Processing of urine specimens.** Each urine specimen was utilized for isolation and
527 identification of colonizing bacterial species, urinalysis via 10-parameter urine reagent test strip
528 (LW Scientific, Lawrenceville, Georgia), and generation of urine glycerol stock for long-term
529 storage and re-isolation if needed. Remaining urine was also frozen at -80°C for future analyses.
530 To determine total CFU/ml of urine, each specimen was diluted 1:100, spiral plated on
531 HardyCHROM UTI agar (Hardy Diagnostics, Santa Maria, California) using using an Eddy Jet 2
532 spiral pater (Neutec Group inc, Farmingdale, NY), and enumerated using a ProtoCOL 3
533 automated colony counter (Synbiosis). For detection of Gram-positive and Gram-negative
534 bacteria, a 1 µl calibrated inoculating loop (Laboratory Products Sales, Inc, Rochester, NY) was
535 used for semi-quantitative streak-plating on three types of agar from Hardy Diagnostics (Santa

536 Maria, California): Columbia CNA, Bile Esculin (BEA), and MacConkey. All distinct colonies
537 that could be differentiated by morphology, hemolysis, or color were isolated for further
538 analysis.

539 Gram-positive bacteria from CNA and BEA plates were tested for catalase using 30%
540 hydrogen peroxide and for PYR activity (Hardy Diagnostics). Isolates that were PYR-positive
541 and catalase-negative were suspected to be *Enterococcus* species, and identified to the species
542 level using previously-described primer sets (92). Isolates that were PYR-negative and catalase-
543 positive were suspected to be *Staphylococcus* species, and subjected to Sure-View™ SELECT
544 (Fisher Healthcare) to distinguish *Staphylococcus aureus* from coagulase-negative
545 *Staphylococcus* species. PYR-negative and catalase-negative isolates were suspected to be
546 *Streptococcus* species, and were subjected to a Streptex™ Latex Agglutination Test (Thermo
547 Scientific). Suspected *Streptococcus* isolates that did not have a positive Streptex reaction were
548 designated “miscellaneous PYR-negative catalase-negative Gram-positive isolates”.

549 Gram-negative bacteria from MacConkey plates were identified to the species level
550 whenever possible using API-20E test strips (BioMérieux, Marcy-l'Étoile, France). Isolates
551 identified as *Pseudomonas aeruginosa* via API-20E were confirmed using previously-described
552 primer sets (93). *Proteus mirabilis* and *Proteus vulgaris* isolates were confirmed by swarming
553 motility on blood agar plates (Hardy Diagnostics).

554 Isolates of a given organism from consecutive urines specimens from the same
555 participant were assumed to be the same strain if they were the same genus and species, the API-
556 20E biotype number varied by no more than two digits (for Gram-negative isolates), and if
557 colony morphology and antimicrobial susceptibility profiles were consistent week-to-week (see
558 below). If a strain was absent in one urine specimen but had been present in the preceding and

559 following specimens from that participant, re-isolation was attempted from the urine glycerol
560 stock. If the strain still could not be detected, it was assumed to be absent from that urine
561 specimen.

562
563 **Antimicrobial susceptibility testing.** Antimicrobial susceptibility was assessed by zone of
564 growth inhibition on Mueller-Hinton agar (Hardy Diagnostics). Zone diameters indicative of
565 susceptibility were determined using the Clinical and Laboratory Standards Institute (CLSI)
566 breakpoints listed in the M100 30th edition (94, 95). *Enterococcus* isolates were tested for
567 vancomycin sensitivity using Etest strips (Hardy Diagnostics), and a minimum inhibitory
568 concentration of ≤ 4 ug/ml was considered susceptible. *S. aureus* isolates were tested for
569 methicillin susceptibility using ceftaxime (Hardy Diagnostics), and susceptibility was defined as a
570 zone diameter of ≥ 18 mm. Gram-negative isolates were tested for susceptibility to ciprofloxacin
571 (Hardy Diagnostics) (≥ 21 mm zone diameter), ceftazidime (Hardy Diagnostics) (≥ 18 mm zone
572 diameter), ceftazidime with clavulanate (Hardy Diagnostics) (≥ 20 mm zone diameter), and
573 imipenem (Hardy Diagnostics) (≥ 15 mm zone diameter).

574
575 **Statistical Analysis.** Logistic regression models and Bayesian multilevel longitudinal models
576 were performed using statistical software R v.4.0.1 (R Core Team 2021, [https://www.r-](https://www.r-project.org/)
577 [project.org/](https://cran.r-project.org/web/packages/rjags/index.html)), and JAGS (<https://cran.r-project.org/web/packages/rjags/index.html>). All logistic
578 regression models were adjusted for participant-level clustering to account for multiple samples
579 per participant. The Bayesian longitudinal models permitted rigorous handling of missing
580 observations in the data.

581 For longitudinal analysis of occurrences of microbial species (and similarly for signs and
582 symptoms), we considered two Bayesian multilevel models – one for analyzing the *likelihood of*
583 *occurrence of each individual species* (and similarly individual signs or symptoms), and another
584 for explaining *the total number of microbial occurrences* (and similarly, sign and symptom
585 occurrences). In the following, we describe the two models used for microbial occurrences;
586 analogous models were used for signs and symptoms.

587 In the first model (model - 1), we quantified the effects of all microbial species, catheter
588 changes, and antibiotic administration on the occurrence of each individual microbial species
589 through a multilevel logistic regression model of the form:

$$\text{logit } P(y_{it} = 1) = \mu + \beta_{\text{cath}} \text{cath}_{i,t} + \beta_{\text{antibio}} \text{antibio}_{i,t}; \quad t = 1;$$

590
$$\text{logit } P(y_{it} = 1) =$$

591
$$\mu + \alpha(t - 1) + \gamma y_{i,t-1} + \sum_j \beta_j x_{i,t-1}^{(j)} + \beta_{\text{cath}} \text{cath}_{i,t} + \beta_{\text{antibio}} \text{antibio}_{i,t}; \quad t \geq 1 ;$$

592 where for an individual i at time point t , y_{it} denotes the binary indicator of a specific *response*
593 *microbe* (e.g. MRSA); $x_{i,t-1}^{(j)}$ denotes the binary 0-1 indicator of the j -th *microbe* other than the
594 *response microbe* at individual i at time $t-1$, and $\text{cath}_{i,t}$ and $\text{antibio}_{i,t}$ denote the binary 0-1
595 indicators of catheter changes and antibiotic administration, respectively. The parameter α
596 quantifies the effect of time, the parameters γ and β_j quantify the logarithms of the odds ratios of
597 the occurrence of the species under consideration, due to one unit change (from 0 (“No”) to 1
598 (“Yes”); while keeping other predictor variables fixed) in the binary presence status of the same
599 species (e.g., MRSA) and j -th other species *at the previous visit*, and the parameters β_{cath} and
600 β_{antibio} measure similar log-odds ratios due to one unit change (while keeping other predictor
601 variables fixed) in the binary presence status indicators of catheter change and antibiotic
602 administration *at the current visit* respectively, and for $0 < p < 1$, $\text{logit } p = \log \frac{p}{1-p}$. Note that

603 through the above logistic regression model, missingness in the *response* microbial species
604 occurrence is naturally addressed within a Bayesian statistical framework. To address
605 missingness in the predictor variables, we considered independent Bernoulli distributions

$$x_{i,t}^{(j)} \sim \text{Bernoulli}(p_j); \text{cath}_{i,t} \sim \text{Bernoulli}(p_{\text{cath}}); \text{antibio}_{i,t} \sim \text{Bernoulli}(p_{\text{antibio}})$$

606 in the second level of the multilevel model. Finally, in the third level of the model we specified
607 (independent, vague) prior distributions for the model parameters. The probability parameters p_j ,
608 p_{cath} , and p_{antibio} were assigned independent flat Uniform(0, 1) prior distributions. The intercept
609 μ was assigned an independent Normal(0, 100²) prior; the regression parameters β_{cath} , β_{antibio} ,
610 α , and γ were assigned independent scale mixture normal priors of the form

611 $\beta_{\text{cath}} \sim \text{Normal}(0, \sigma_{\text{cath}}^2)$; $\sigma_{\text{cath}}^2 \sim \text{inverse-Gamma}(0.001, 0.001)$ (similarly for β_{antibio} , α , and
612 γ). Finally, for the regression coefficients of all ‘other’ microbes, induced shrinkage normal scale
613 mixture priors of the form $\beta_j = \frac{\tilde{\beta}_j}{\text{sd}(x_{i,t}^{(j)})}$; $\tilde{\beta}_j \sim \text{Normal}(0, \sigma_{\beta}^2)$;
614 $\sigma_{\beta}^2 \sim \text{inverse-Gamma}(0.001, 0.001)$ were considered.

615 In the second model (model – 2), assuming exchangeability of the occurrence of
616 individual microbial species at a given time point in a specific individual, we considered a
617 multilevel Binomial regression model of the form

$$n_{i,t} \sim \text{Binomial}(M, p_{i,t})$$

$$\text{logit } p_{i,t} = \mu + \beta_{\text{cath}} \text{cath}_{i,t} + \beta_{\text{antibio}} \text{antibio}_{i,t}; t = 1$$

$$\text{logit } p_{i,t} = \mu + \alpha(t - 1) + \lambda n_{i,t-1} + \beta_{\text{cath}} \text{cath}_{i,t} + \beta_{\text{antibio}} \text{antibio}_{i,t}; t \geq 2$$

618 Where $n_{i,t}$ is the total number (counts) of observed microbial species, and $p_{i,t}$ is the
619 corresponding probability of observing *one generic* microbial species, in subject i at time t , and
620 M denotes the total number of microbial species considered in the study ($M = 21$). Here λ

621 quantifies the log-odds ratio of the occurrence of a *generic* microbial species at time t in
622 individual i for a one unit increase in the microbial species counts in the same individual at the
623 previous visit, and the remaining parameters have analogous interpretations as in model – 1, with
624 a specific response microbial species being replaced by a *generic* species. Similar to model – 1,
625 missingness in the response $n_{i,t}$ are addressed naturally through the model in a Bayesian
626 framework. Missingness in the catheter change and antibiotic administration data are addressed
627 through a similar second (Bernoulli) level:

$$\text{cath}_{i,t} \sim \text{Bernoulli}(p_{\text{cath}}); \text{antibio}_{i,t} \sim \text{Bernoulli}(p_{\text{antibio}})$$

628 In the final level, independent vague prior distributions similar to model – 1 are considered for
629 the model parameters.

630 We first fitted model – 1 separately on each response microbial species (and similarly on
631 each response sign or symptom), and then fitted model – 2 collectively on all species (and
632 similarly on all signs and symptoms), by approximating their respective posterior distributions
633 through 10,000 Markov chain Monte Carlo (MCMC) draws, after discarding 10,000 burn-in
634 draws, all generated using JAGS. In a typical Bayesian fashion, missing values in the data were
635 augmented with the respective posterior distributions during the analysis based on the models
636 described above, and were subsequently integrated (marginalized) out. Finally, using the MCMC
637 draws the resulting (marginal) posterior distributions of the various model parameters of interest
638 were summarized through their posterior medians and 95% credible intervals (computed through
639 0.025th and 0.975th posterior quantiles). These summaries are displayed as forest plots in
640 Supplementary Figures 5 and 6.

641 **Acknowledgments**

642 We would like to thank members of the Department of Microbiology & Immunology, the
643 Division of Infectious Diseases, and Witebsky Center for Microbial Pathogenesis and
644 Immunology for helpful comments and critiques. We would also like to thank the nursing home
645 administrators and staff, as well as the Visiting Nurse Association of Western New York. This
646 work was supported by the National Institutes of Health via the National Institute of Diabetes
647 Digestive and Kidney Diseases [R00 DK105205 and R01 DK123158 to C.E.A.] and the National
648 Center for Advancing Translational Sciences (UL1 TR001412 to the University at Buffalo). The
649 sponsors were not involved in the study design, methods, subject recruitment, data collections,
650 analysis, or preparation of the paper. The content is solely the responsibility of the authors and
651 does not necessarily represent the official views of the funders.

652

653 **Author Contributions**

654 Conceptualization, C.E.A.; Methodology, C.E.A. and S.C.; Validation, C.E.A. and A.L.B.;
655 Formal Analysis, C.E.A., A.L.B., M.S.H., J.S., and S.C.; Investigation, C.E.A., A.L.B., M.S.H.,
656 J.S., and S.C.; Resources, C.E.A.; Data Curation, C.E.A., A.L.B., and M.S.H.; Writing – Original
657 Draft Preparation, C.E.A.; Writing – Review & Editing, all authors.; Visualization, C.E.A. and
658 S.C.; Supervision, C.E.A. and S.C.; Project Administration, C.E.A.; Funding Acquisition,
659 C.E.A..

660

661 **Competing Interests**

662 The authors have no financial or non-financial competing interests to declare.

663 **References**

- 664 1. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al.
665 Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in
666 Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases
667 Society of America. *Clinical Infectious Diseases*. 2010;50(5):625-63.
- 668 2. Nicolle LE. Urinary Catheter-Associated Infections. *Infectious Disease Clinics of North*
669 *America*. 2012;26(1):13-27.
- 670 3. Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, et al.
671 National Healthcare Safety Network report, data summary for 2013, Device-associated
672 Module. *Am J Infect Control*. 2015;43(3):206-21.
- 673 4. Rogers MAM, Mody L, Kaufman SR, Fries BE, McMahon LF, and Saint S. Use of
674 Urinary Collection Devices in Skilled Nursing Facilities in Five States. *Journal of the*
675 *American Geriatrics Society*. 2008;56(5):854-61.
- 676 5. Tsan L, Langberg R, Davis C, Phillips Y, Pierce J, Hojlo C, et al. Nursing home-
677 associated infections in Department of Veterans Affairs community living centers.
678 *American Journal of Infection Control*. 2010;38(6):461-6.
- 679 6. Kunin CM, Douthitt S, Dancing J, Anderson J, and Moeschberger M. The Association
680 between the Use of Urinary Catheters and Morbidity and Mortality among Elderly
681 Patients in Nursing-Homes. *American journal of epidemiology*. 1992;135(3):291-301.
- 682 7. Crnich CJ, and Drinka P. Medical device-associated infections in the long-term care
683 setting. *Infect Dis Clin North Am*. 2012;26(1):143-64.
- 684 8. Nicolle LE. Catheter associated urinary tract infections. *Antimicrob Resist In*. 2014;3.

- 685 9. Mody L, Greene MT, Meddings J, Krein SL, McNamara SE, Trautner BW, et al. A
686 National Implementation Project to Prevent Catheter-Associated Urinary Tract Infection
687 in Nursing Home Residents. *JAMA internal medicine*. 2017;177(8):1154-62.
- 688 10. Mody L, Krein SL, Saint S, and et al. A targeted infection prevention intervention in
689 nursing home residents with indwelling devices: A randomized clinical trial. *JAMA*
690 *Internal Medicine*. 2015;175(5):714-23.
- 691 11. Wang L, Lansing B, Symons K, Flannery EL, Fisch J, Cherian K, et al. Infection rate and
692 colonization with antibiotic-resistant organisms in skilled nursing facility residents with
693 indwelling devices. *Eur J Clin Microbiol Infect Dis*. 2012;31(8):1797-804.
- 694 12. Garcia MM, Gulati S, Liepmann D, Stackhouse GB, Greene K, and Stoller ML.
695 Traditional Foley Drainage Systems—Do They Drain the Bladder? *The Journal of*
696 *Urology*. 2007;177(1):203-7.
- 697 13. Willette PA, and Coffield SK. Current Trends in the Management of Difficult Urinary
698 Catheterizations. *Western Journal of Emergency Medicine*. 2012;13(6).
- 699 14. Armbruster C, Mobley H, and Pearson M. Pathogenesis of *Proteus mirabilis* Infection.
700 *EcoSal Plus*. 2018.
- 701 15. Hofseth LJ, Dunn BP, and Rosin MP. Micronucleus frequencies in urothelial cells of
702 catheterized patients with chronic bladder inflammation. *Mutation*
703 *Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 1996;352(1–2):65-
704 72.
- 705 16. Anderson RU. Response of bladder and urethral mucosa to catheterization. *JAMA*.
706 1979;242(5):451-3.

- 707 17. Armbruster CE, Smith SN, Johnson AO, DeOrnellas V, Eaton KA, Yep A, et al. The
708 Pathogenic Potential of *Proteus mirabilis* is Enhanced by Other Uropathogens During
709 Polymicrobial Urinary Tract Infection. *Infection and Immunity*. 2017;85(2):e00808-16.
- 710 18. Nicolle LE. Catheter-related urinary tract infection: practical management in the elderly.
711 *Drugs Aging*. 2014;31(1):1-10.
- 712 19. Daniels KR, Lee GC, and Frei CR. Trends in catheter-associated urinary tract infections
713 among a national cohort of hospitalized adults, 2001-2010. *American Journal of Infection
714 Control*. 2014;42(1):17-22.
- 715 20. Warren JW, Damron D, Tenney JH, Hoopes JM, Deforge B, and Muncie HL, Jr. Fever,
716 bacteremia, and death as complications of bacteriuria in women with long-term urethral
717 catheters. *J Infect Dis*. 1987;155(6):1151-8.
- 718 21. Bootsma AM, Buurman BM, Geerlings SE, and de Rooij SE. Urinary incontinence and
719 indwelling urinary catheters in acutely admitted elderly patients: relationship with
720 mortality, institutionalization, and functional decline. *J Am Med Dir Assoc*.
721 2013;14(2):147 e7-12.
- 722 22. Chant C, Smith OM, Marshall JC, and Friedrich JO. Relationship of catheter-associated
723 urinary tract infection to mortality and length of stay in critically ill patients: a systematic
724 review and meta-analysis of observational studies. *Crit Care Med*. 2011;39(5):1167-73.
- 725 23. Esparcia A, Artero A, Eiros JM, Balaguer M, Madrazo M, Alberola J, et al. Influence of
726 inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract
727 infections. *Eur J Intern Med*. 2014;25(6):523-7.
- 728 24. Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, et al. Development
729 of minimum criteria for the initiation of antibiotics in residents of long-term-care

- 730 facilities: results of a consensus conference. *Infect Control Hosp Epidemiol.*
731 2001;22(2):120-4.
- 732 25. Stone ND, Ashraf MS, Calder J, Crnich CJ, Crossley K, Drinka PJ, et al. Surveillance
733 definitions of infections in long-term care facilities: revisiting the McGeer criteria. *Infect*
734 *Control Hosp Epidemiol.* 2012;33(10):965-77.
- 735 26. Fekete T. Catheter-associated urinary tract infection in adults.
736 <https://www.uptodate.com/contents/catheter-associated-urinary-tract-infection-in-adults>.
737 Accessed September 27, 2020, 2020.
- 738 27. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical
739 Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by
740 the Infectious Diseases Society of Americaa. *Clinical Infectious Diseases.*
741 2019;68(10):1611-5.
- 742 28. (NHSN) NHSN. Atlanta, GA: Division of Healthcare Quality Promotion, National Center
743 for Emergine and Zoonotic Infectious Diseases; 2020.
- 744 29. High K. Evaluation of infection in the older adult.
745 [http://www.uptodate.com/contents/evaluation-of-infection-in-the-older-](http://www.uptodate.com/contents/evaluation-of-infection-in-the-older-adult?source=see_link)
746 [adult?source=see link](http://www.uptodate.com/contents/evaluation-of-infection-in-the-older-adult?source=see_link). Accessed 04/10/2016, 2016.
- 747 30. Mouton CP, Bazaldua OV, Pierce B, and Espino DV. Common infections in older adults.
748 *Am Fam Physician.* 2001;63(2):257-68.
- 749 31. Armbruster CE, Prenovost K, Mobley HLT, and Mody L. How Often Do Clinically
750 Diagnosed Catheter-Associated Urinary Tract Infections in Nursing Home Residents
751 Meet Standardized Criteria? *J Am Geriatr Soc.* 2017;65(2):395-401.

- 752 32. Tambyah PA, and Maki DG. Catheter-associated urinary tract infection is rarely
753 symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med*.
754 2000;160(5):678-82.
- 755 33. Cope M, Cevallos ME, Cadle RM, Darouiche RO, Musher DM, and Trautner BW.
756 Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care
757 hospital. *Clin Infect Dis*. 2009;48(9):1182-8.
- 758 34. Kizilbash QF, Petersen NJ, Chen GJ, Naik AD, and Trautner BW. Bacteremia and
759 mortality with urinary catheter-associated bacteriuria. *Infect Control Hosp Epidemiol*.
760 2013;34(11):1153-9.
- 761 35. Shortliffe LMD, and McCue JD. Urinary tract infection at the age extremes: pediatrics
762 and geriatrics. *The American Journal of Medicine*. 2002;113(1, Supplement 1):55-66.
- 763 36. Mayne S, Sundvall P-D, and Gunnarsson R. Confusion Strongly Associated with
764 Antibiotic Prescribing Due to Suspected Urinary Tract Infections in Nursing Homes.
765 *Journal of the American Geriatrics Society*. 2018;66(2):274-81.
- 766 37. Nicolle LE. Asymptomatic Bacteriuria and Bacterial Interference. *Microbiology*
767 *spectrum*. 2015;3(5).
- 768 38. Nace DA, Drinka PJ, and Crnich CJ. Clinical uncertainties in the approach to long term
769 care residents with possible urinary tract infection. *J Am Med Dir Assoc*. 2014;15(2):133-
770 9.
- 771 39. Agata ED, Loeb MB, and Mitchell SL. Challenges in Assessing Nursing Home Residents
772 with Advanced Dementia for Suspected Urinary Tract Infections. *Journal of the*
773 *American Geriatrics Society*. 2013;61(1):62-6.

- 774 40. Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Van Ness PH, and Quagliarello V.
775 Interobserver variability in the assessment of clinical criteria for suspected urinary tract
776 infection in nursing home residents. *Infection control and hospital epidemiology*.
777 2008;29(5):446-9.
- 778 41. Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, and Tinetti M.
779 Clinical Features to Identify Urinary Tract Infection in Nursing Home Residents: A
780 Cohort Study. *Journal of the American Geriatrics Society*. 2009;57(6):963-70.
- 781 42. Dedeic-Ljubovic A, and Hukic M. Catheter-related urinary tract infection in patients
782 suffering from spinal cord injuries. *Bosn J Basic Med Sci*. 2009;9(1):2-9.
- 783 43. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens.
784 *Dis Mon*. 2003;49(2):71-82.
- 785 44. Siegman-Igra Y, Kulka T, Schwartz D, and Konforti N. Polymicrobial and
786 monomicrobial bacteraemic urinary tract infection. *Journal of Hospital Infection*.
787 1994;28(1):49-56.
- 788 45. Kunin CM. Blockage of urinary catheters: Role of microorganisms and constituents of
789 the urine on formation of encrustations. *Journal of Clinical Epidemiology*.
790 1989;42(9):835-42.
- 791 46. Rahav G, Pinco E, Silbaq F, and Bercovier H. Molecular epidemiology of catheter-
792 associated bacteriuria in nursing home patients. *J Clin Microbiol*. 1994;32(4):1031-4.
- 793 47. Mobley HLT, and Warren JW. Urease-Positive Bacteriuria and Obstruction of Long-
794 Term Urinary Catheters. *J Clin Microbiol*. 1987;25(11):2216-7.
- 795 48. Breitenbucher RB. Bacterial changes in the urine samples of patients with long-term
796 indwelling catheters. *Arch Intern Med*. 1984;144(8):1585-8.

- 797 49. Warren JW, Tenney JH, Hoopes JM, Muncie HL, and Anthony WC. A Prospective
798 Microbiologic Study of Bacteriuria in Patients with Chronic Indwelling Urethral
799 Catheters. *Journal of Infectious Diseases*. 1982;146(6):719-23.
- 800 50. Nicolle LE. Catheter-Related Urinary Tract Infection. *Drugs & Aging*. 2005;22(8):627-
801 39.
- 802 51. Armbruster CE, and Mobley HLT. Merging mythology and morphology: the multifaceted
803 lifestyle of *Proteus mirabilis*. *Nat Rev Micro*. 2012;10(11):743-54.
- 804 52. Jonsson K, Claesson BE, and Hedelin H. Urine cultures from indwelling bladder
805 catheters in nursing home patients: a point prevalence study in a Swedish county. *Scand J*
806 *Urol Nephrol*. 2011;45(4):265-9.
- 807 53. Fourcade C, Canini L, Lavigne JP, and Sotto A. A comparison of monomicrobial versus
808 polymicrobial *Enterococcus faecalis* bacteriuria in a French University Hospital. *Eur J*
809 *Clin Microbiol Infect Dis*. 2015;34(8):1667-73.
- 810 54. Schaeffer AJ. Catheter-associated bacteriuria. *Urol Clin North Am*. 1986;13(4):735-47.
- 811 55. Lawton MP, and Brody EM. Assessment of older people: self-maintaining and
812 instrumental activities of daily living. *Gerontologist*. 1969;9(3):179-86.
- 813 56. Murray JL, Connell JL, Stacy A, Turner KH, and Whiteley M. Mechanisms of synergy in
814 polymicrobial infections. *Journal of Microbiology*. 2014;52(3):188-99.
- 815 57. Nair N, Biswas R, Götz F, and Biswas L. Impact of *Staphylococcus aureus* on
816 Pathogenesis in Polymicrobial Infections. *Infection and Immunity*. 2014;82(6):2162-9.
- 817 58. Short FL, Murdoch SL, and Ryan RP. Polybacterial human disease: the ills of social
818 networking. *Trends in Microbiology*. 2014;22(9):508-16.

- 819 59. Tay WH, Chong KK, and Kline KA. Polymicrobial-Host Interactions during Infection. *J*
820 *Mol Biol.* 2016.
- 821 60. Learman BS, Brauer AL, Eaton KA, and Armbruster CE. A Rare Opportunist,
822 *Morganella morganii*, Decreases Severity of Polymicrobial Catheter-Associated Urinary
823 Tract Infection. *Infection and Immunity.* 2019;88(1):e00691-19.
- 824 61. Hajishengallis G, and Lamont RJ. Dancing with the Stars: How Choreographed Bacterial
825 Interactions Dictate Nososymbiocity and Give Rise to Keystone Pathogens, Accessory
826 Pathogens, and Pathobionts. *Trends in Microbiology.* 2016;24(6):477-89.
- 827 62. Lin LI. A concordance correlation coefficient to evaluate reproducibility. *Biometrics.*
828 1989;45(1):255-68.
- 829 63. Loeb M, Brazil K, Lohfeld L, McGeer A, Simor A, Stevenson K, et al. Optimizing
830 antibiotics in residents of nursing homes: protocol of a randomized trial. *BMC health*
831 *services research.* 2002;2(1):17.
- 832 64. Loeb M, Simor AE, Landry L, Walter S, McArthur M, Duffy J, et al. Antibiotic use in
833 Ontario facilities that provide chronic care. *Journal of general internal medicine.*
834 2001;16(6):376-83.
- 835 65. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious
836 Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic
837 bacteriuria in adults. *Clin Infect Dis.* 2005;40(5):643-54.
- 838 66. Smith M-A, Puckrin R, Lam PW, Lamb MJ, Simor AE, and Leis JA. Association of
839 Increased Colony-Count Threshold for Urinary Pathogens in Hospitalized Patients With
840 Antimicrobial Treatment. *JAMA Internal Medicine.* 2019;179(7):990-2.

- 841 67. Leis JA, Rebick GW, Daneman N, Gold WL, Poutanen SM, Lo P, et al. Reducing
842 Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients:
843 A Proof-of-Concept Study. *Clinical Infectious Diseases*. 2014;58(7):980-3.
- 844 68. Petty LA, Vaughn VM, Flanders SA, Malani AN, Conlon A, Kaye KS, et al. Risk Factors
845 and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized
846 Patients. *JAMA Internal Medicine*. 2019;179(11):1519-27.
- 847 69. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, et al. Management
848 of Bacteriuria in Veterans Affairs Hospitals. *Clin Infect Dis*. 2017;65(6):910-7.
- 849 70. Hartley S, Valley S, Kuhn L, Washer LL, Gandhi T, Meddings J, et al. Overtreatment of
850 Asymptomatic Bacteriuria: Identifying Targets for Improvement. *Infection Control &
851 Hospital Epidemiology*. 2015;36(4):470-3.
- 852 71. Leuck A-M, Wright D, Ellingson L, Kraemer L, Kuskowski MA, and Johnson JR.
853 Complications of Foley Catheters—Is Infection the Greatest Risk? *Journal of
854 Urology*. 2012;187(5):1662-6.
- 855 72. Das R, Towle V, Van Ness PH, and Juthani-Mehta M. Adverse outcomes in nursing
856 home residents with increased episodes of observed bacteriuria. *Infect Control Hosp
857 Epidemiol*. 2011;32(1):84-6.
- 858 73. Gupta K, O'Brien W, Gallegos-Salazar J, Strymish J, and Branch-Elliman W. How
859 Testing Drives Treatment in Asymptomatic Patients: Level of Pyuria Directly Predicts
860 Probability of Antimicrobial Prescribing. *Clin Infect Dis*. 2020;71(3):614-21.
- 861 74. Tambyah PA, and Maki DG. The Relationship Between Pyuria and Infection in Patients
862 With Indwelling Urinary Catheters: A Prospective Study of 761 Patients. *Archives of
863 Internal Medicine*. 2000;160(5):673-7.

- 864 75. Tambyah PA, and Maki DG. Catheter-Associated Urinary Tract Infection Is Rarely
865 Symptomatic: A Prospective Study of 1497 Catheterized Patients. *Archives of Internal*
866 *Medicine*. 2000;160(5):678-82.
- 867 76. Orr PH, Nicolle LE, Duckworth H, Brunka J, Kennedy J, Murray D, et al. Febrile urinary
868 infection in the institutionalized elderly. *The American Journal of Medicine*.
869 1996;100(1):71-7.
- 870 77. Kunin CM, Chin QF, and Chambers S. Morbidity and Mortality Associated with
871 Indwelling Urinary Catheters in Elderly Patients in a Nursing Home—Confounding Due
872 to the Presence of Associated Diseases. *Journal of the American Geriatrics Society*.
873 1987;35(11):1001-6.
- 874 78. Mody L, and Juthani-Mehta M. Urinary tract infections in older women: a clinical
875 review. *JAMA*. 2014;311(8):844-54.
- 876 79. Tornic J, Wöllner J, Leitner L, Mehnert U, Bachmann LM, and Kessler TM. The
877 Challenge of Asymptomatic Bacteriuria and Symptomatic Urinary Tract Infections in
878 Patients with Neurogenic Lower Urinary Tract Dysfunction. *Journal of Urology*.
879 2020;203(3):579-84.
- 880 80. Tedja R, Wentink J, O’Horo JC, Thompson R, and Sampathkumar P. Catheter-
881 Associated Urinary Tract Infections in Intensive Care Unit Patients. *Infection Control &*
882 *Hospital Epidemiology*. 2015;36(11):1330-4.
- 883 81. RAZ R, SCHILLER D, and NICOLLE LE. CHRONIC INDWELLING CATHETER
884 REPLACEMENT BEFORE ANTIMICROBIAL THERAPY FOR SYMPTOMATIC
885 URINARY TRACT INFECTION. *Journal of Urology*. 2000;164(4):1254-8.

- 886 82. Babich T, Zusman O, Elbaz M, Ben-Zvi H, Paul M, Leibovici L, et al. Replacement of
887 Urinary Catheter for Urinary Tract Infections: A Prospective Observational Study.
888 *Journal of the American Geriatrics Society*. 2018;66(9):1779-84.
- 889 83. Kline KA, and Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract
890 Infection, and the Emerging Microbiota of the Urinary Tract. *Microbiology spectrum*.
891 2016;4(2).
- 892 84. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *The New England*
893 *journal of medicine*. 2012;366(11):1028-37.
- 894 85. Chenoweth CE, Gould CV, and Saint S. Diagnosis, management, and prevention of
895 catheter-associated urinary tract infections. *Infect Dis Clin North Am*. 2014;28(1):105-19.
- 896 86. Bregenzer T, Frei R, Widmer AF, Seiler W, Probst W, Mattarelli G, et al. Low Risk of
897 Bacteremia During Catheter Replacement in Patients With Long-term Urinary Catheters.
898 *Archives of Internal Medicine*. 1997;157(5):521-5.
- 899 87. Stokes W, Parkins MD, Parfitt ECT, Ruiz JC, Mugford G, and Gregson DB. Incidence
900 and Outcomes of *Staphylococcus aureus* Bacteriuria: A Population-based Study. *Clinical*
901 *Infectious Diseases*. 2018;69(6):963-9.
- 902 88. Armbruster CE, Smith SN, Yep A, and Mobley HLT. Increased Incidence of Urolithiasis
903 and Bacteremia During *Proteus mirabilis* and *Providencia stuartii* Coinfection Due to
904 Synergistic Induction of Urease Activity. *Journal of Infectious Diseases*.
905 2014;209(10):1524-32.
- 906 89. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
907 consortium: Building an international community of software platform partners. *J*
908 *Biomed Inform*. 2019;95:103208.

- 909 90. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, and Conde JG. Research electronic
910 data capture (REDCap)--a metadata-driven methodology and workflow process for
911 providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-
912 81.
- 913 91. Han JH, Wilson A, Vasilevskis EE, Shintani A, Schnelle JF, Dittus RS, et al. Diagnosing
914 delirium in older emergency department patients: validity and reliability of the delirium
915 triage screen and the brief confusion assessment method. *Ann Emerg Med.*
916 2013;62(5):457-65.
- 917 92. Layton BA, Walters SP, Lam LH, and Boehm AB. Enterococcus species distribution
918 among human and animal hosts using multiplex PCR. *Journal of Applied Microbiology.*
919 2010;109(2):539-47.
- 920 93. Spilker T, Coenye T, Vandamme P, and LiPuma JJ. PCR-Based Assay for Differentiation
921 of *Pseudomonas aeruginosa* from Other *Pseudomonas* Species Recovered from Cystic
922 Fibrosis Patients. *J Clin Microbiol.* 2004;42(5):2074-9.
- 923 94. Weinstein MP, Lewis JS, Bobenchik AM, Campeau S, Cullen SK, Galas MF, et al.
924 M100: Performance Standards for Antimicrobial Susceptibility Testing. *Clinical and*
925 *Laboratory Standards Institute.* 2020.
- 926 95. Humphries RM, Abbott AN, and Hindler JA. Understanding and Addressing CLSI
927 Breakpoint Revisions: a Primer for Clinical Laboratories. *J Clin Microbiol.* 2019;57(6).

928

929

930 **Table 1.** Characteristics of study participants.

| | |
|--|-------------------|
| Age, mean (SD;range), years | 65 (15;43-91) |
| Weight, mean (SD;range), pounds | 182 (26;117-220) |
| PSMS, mean (SD;range) | 22 (4;13-27) |
| Duration of catheter use (years), mean (SD;range) ^a | 6.5 (4.7; 1-17) |
| Duration of follow-up (weeks), mean (SD; range) | 13.0 (11.0; 1-30) |
| Number of catheter changes, mean (SD;range) | 2.6 (3.6; 0-12) |
| Gender | |
| Male | 15 (79) |
| Female | 4 (21) |
| Race | |
| White | 15 (79) |
| Black or African American | 4 (21) |
| Catheter type | |
| Foley | 6 (32) |
| Suprapubic | 13 (68) |
| Indication for catheter use | |
| Urinary retention or outlet obstruction | 19 (100) |
| Facility | |
| A | 8 (42) |
| B | 11 (58) |
| Underlying conditions | |
| Neurogenic bladder | 14 (74) |
| Hemiplegia | 8 (42) |
| Diabetes | 6 (32) |
| Renal disease | 6 (32) |
| Multiple sclerosis | 5 (26) |
| Chronic heart failure | 5 (26) |
| Dementia | 4 (21) |

931 Data are No. (%) of residents, unless otherwise indicated. SD, standard deviation; PSMS,
 932 physical self-maintenance score.

933 ^aIf date of first catheter placement could not be determined, date of admission to facility with
 934 catheter in place was utilized.

935 **Table 2.** Prevalence of antimicrobial resistant isolates

| Organism | Resistance | ^aParticipant Prevalence | ^bOrganism Prevalence |
|--|-------------------|---|--|
| <i>Staphylococcus aureus</i> (13 participants, 168 isolates) | Methicillin | 9 (69) | 81 (48) |
| <i>Proteus mirabilis</i> (11 participants, 118 isolates) | Ciprofloxacin | 7 (64) | 81 (69) |
| <i>Providencia stuartii</i> (9 participants, 111 isolates) | Ciprofloxacin | 4 (44) | 27 (24) |
| | ESBL | 1 (11) | 22 (20) |
| <i>Morganella morganii</i> (5 participants, 64 isolates) | Ciprofloxacin | 2 (40) | 24 (37) |
| <i>Escherichia coli</i> (8 participants, 89 isolates) | Ciprofloxacin | 1 (12) | 26 (29) |
| <i>Pseudomonas aeruginosa</i> (8 participants, 66 isolates) | Ciprofloxacin | 3 (37) | 10 (15) |
| | ESBL | 2 (25) | 12 (18) |
| <i>Proteus vulgaris</i> (3 participants, 37 isolates) | Ciprofloxacin | 2 (67) | 3 (8) |
| <i>Klebsiella oxytoca</i> (3 participants, 16 isolates) | ESBL | 1 (33) | 2 (12) |
| <i>Enterobacter aerogenes</i> (2 participants, 8 isolates) | ESBL | 1 (50) | 1 (12) |

936 ^aNumber (percent) of study participants colonized by the organism with isolates resistant to the
 937 listed antimicrobial

938 ^bNumber (percent) of isolates of the organism that were resistant to the listed antimicrobial

939 **Table 3.** Epidemiology of Catheter-Associated Bacteriuria

| | Baseline Occurrence | ^a Point prevalence | Patient weeks | ^b Weekly prevalence | New episodes | ^c Incidence | Number of one-week episodes | ^d Proportion of one-week episodes |
|-------------------------------|---------------------|-------------------------------|---------------|--------------------------------|--------------|------------------------|-----------------------------|--|
| <i>Enterococcus faecalis</i> | 14 | 0.74 | 163 | 0.63 | 4 | 0.02 | 0 | 0.00 |
| <i>Proteus mirabilis</i> | 6 | 0.32 | 118 | 0.45 | 5 | 0.02 | 0 | 0.00 |
| <i>Providencia stuartii</i> | 8 | 0.42 | 111 | 0.43 | 6 | 0.02 | 0 | 0.00 |
| <i>Escherichia coli</i> | 7 | 0.37 | 89 | 0.34 | 3 | 0.01 | 0 | 0.00 |
| MSSA | 5 | 0.26 | 87 | 0.33 | 8 | 0.03 | 2 | 0.25 |
| MRSA | 5 | 0.26 | 81 | 0.31 | 12 | 0.05 | 5 | 0.42 |
| <i>Pseudomonas aeruginosa</i> | 4 | 0.21 | 66 | 0.25 | 18 | 0.07 | 6 | 0.33 |
| <i>Morganella morganii</i> | 2 | 0.11 | 64 | 0.25 | 14 | 0.05 | 4 | 0.29 |
| CNS | 7 | 0.37 | 46 | 0.18 | 12 | 0.05 | 6 | 0.50 |
| <i>Providencia rettgeri</i> | 1 | 0.05 | 43 | 0.17 | 9 | 0.03 | 6 | 0.67 |
| <i>Proteus vulgaris</i> | 0 | 0.00 | 37 | 0.14 | 3 | 0.01 | 1 | 0.33 |
| <i>Klebsiella pneumoniae</i> | 2 | 0.11 | 28 | 0.11 | 7 | 0.03 | 3 | 0.43 |
| <i>Klebsiella oxytoca</i> | 0 | 0.00 | 16 | 0.06 | 3 | 0.01 | 0 | 0.00 |
| <i>Serratia marsescens</i> | 1 | 0.05 | 14 | 0.05 | 2 | 0.01 | 2 | 1.00 |
| <i>Enterobacter aerogenes</i> | 2 | 0.11 | 8 | 0.03 | 0 | 0.00 | 0 | NA |
| GBS | 2 | 0.11 | 2 | 0.01 | 0 | 0.00 | 0 | NA |

940 MSSA, methicillin-sensitive *Staphylococcus aureus*; MRSA, methicillin-resistant

941 *Staphylococcus aureus*; CNS, coagulase-negative *Staphylococcus*; GBS, Group B *Streptococcus*.

942 ^a Number of baseline urine specimens with organism divided by the total number of baseline
943 urines

944 ^b Number of patient-weeks the organism was detected divided by total number of patient-weeks

945 ^c Number of new acquisitions of the organism divided by total number of patient-weeks

946 ^d Number of episodes lasting only one week divided by the number of new episodes (excluding
947 the first and last study visits)

948 **Table 4.** Clinical Presentation of Catheter-Associated Bacteriuria

| | Baseline Occurrence | ^a Point prevalence | Patient weeks | ^b Weekly prevalence | New episodes | ^c Incidence | Number of one-week episodes | ^d Proportion of one-week episodes |
|------------------------------------|---------------------|-------------------------------|---------------|--------------------------------|--------------|------------------------|-----------------------------|--|
| ≥10 ⁵ CFU/ml | 19 | 1.00 | 231 | 0.99 | 1 | 0.00 | 0 | 0.00 |
| Hypotension | 3 | 0.16 | 36 | 0.14 | 14 | 0.05 | 7 | 0.50 |
| Fatigue | 3 | 0.16 | 46 | 0.18 | 13 | 0.05 | 8 | 0.62 |
| ^e Altered mental status | 2 | 0.11 | 48 | 0.18 | 26 | 0.10 | 14 | 0.54 |
| Lack of appetite | 3 | 0.16 | 43 | 0.17 | 17 | 0.07 | 12 | 0.71 |
| ^f Pain | 2 | 0.11 | 38 | 0.15 | 10 | 0.04 | 6 | 0.60 |
| Nausea | 2 | 0.11 | 31 | 0.12 | 11 | 0.04 | 5 | 0.45 |
| ^g Fever | 0 | 0.00 | 11 | 0.04 | 11 | 0.04 | 11 | 1.00 |
| Chills | 0 | 0.00 | 10 | 0.04 | 7 | 0.03 | 4 | 0.57 |
| Leukocytosis | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |

949 ^a Number of baseline visits with symptom divided by the total number of baseline visits

950 ^b Number of patient-weeks symptom was detected divided by total number of patient-weeks

951 ^c Number of new instances of symptom divided by total number of patient-weeks

952 ^d Number of episodes lasting only one week divided by the number of new episodes (excluding
953 the first and last study visits)

954 ^e Altered mental status was assessed by bCAM and DTS (see methods)

955 ^f Pain refers to costovertebral or suprapubic pain or tenderness

956 ^g Fever was defined as having a temperature >99°F

957 **Table 5.** Urinalysis of Catheter-Associated Bacteriuria

| | Baseline Occurrence | ^a Point prevalence | Patient weeks | ^b Weekly prevalence | New episodes | ^c Incidence | Number of one-week episodes | ^d Proportion of one-week episodes |
|----------------|---------------------|-------------------------------|---------------|--------------------------------|--------------|------------------------|-----------------------------|--|
| Leukocytes | 17 | 0.89 | 213 | 0.91 | 8 | 0.03 | 0 | 0 |
| Protein | 10 | 0.53 | 131 | 0.56 | 30 | 0.13 | 13 | 0.43 |
| Nitrite | 10 | 0.53 | 124 | 0.53 | 36 | 0.15 | 16 | 0.44 |
| Blood | 8 | 0.42 | 75 | 0.32 | 14 | 0.06 | 12 | 0.86 |
| pH \geq 7.25 | 4 | 0.21 | 105 | 0.45 | 29 | 0.12 | 4 | 0.14 |
| Ketone | 0 | 0.00 | 14 | 0.06 | 9 | 0.04 | 6 | 0.67 |
| Urobilinogen | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |
| Bilirubin | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |
| Glucose | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |

958 ^a Number of baseline urine urinalysis finding divided by the total number of baseline urines

959 ^b Number of patient-weeks urinalysis finding was detected divided by total number of patient-
960 weeks

961 ^c Number of new instances of urinalysis finding divided by total number of patient-weeks

962 ^d Number of episodes lasting only one week divided by the number of new episodes (excluding
963 the first and last study visits)

964

965 **Table 6.** Colonization Dynamics

| Participant | Number of events | Isolates lost ^a | Isolates re-gained ^b | New isolates ^c | New ARO ^d | Incidence of new ARO ^e | Net change ^f |
|---------------------------------|------------------|----------------------------|---------------------------------|---------------------------|----------------------|-----------------------------------|-------------------------|
| Catheter Changes | | | | | | | |
| A | 7 | 7 | 4 | 6 | 0 | NA | +3 |
| B | 5 | 1 | 0 | 0 | 1 | 0.17 | -1 |
| C | 11 | 12 | 11 | 9 | 1 | 0.11 | +8 |
| D | 2 | 0 | 0 | 1 | 0 | NA | +1 |
| E | 2 | 2 | 0 | 5 | 1 | 1.00 | +3 |
| G | 7 | 4 | 4 | 1 | 2 | 0.40 | +1 |
| H | 4 | 2 | 1 | 0 | 0 | 0.00 | -1 |
| I | 2 | 0 | 0 | 1 | 0 | NA | +1 |
| <i>Average</i> | 5.0 | 3.5 | 2.5 | 2.9 | 0.6 | 0.28 | +1.9 |
| Antimicrobial Treatments | | | | | | | |
| B | 1 | 5 | 3 | 2 | 0 | 0.00 | 0 |
| F | 1 | 1 | 0 | 2 | 0 | 0.00 | +1 |
| G | 1 | 2 | 1 | 1 | 1 | 0.50 | 0 |
| <i>Average</i> | 1.0 | 2.7 | 1.3 | 1.7 | 0.3 | 0.17 | +0.3 |

966 Data pertain to all catheter changes and antimicrobial treatments with at least 3 weeks of
 967 subsequent follow-up from 9 study participants who completed at least 16 weeks of follow-up
 968 visits.

969 ^a Number of isolates present the week prior to the event and absent the week following the event

970 ^b Number of isolates that were lost due to the event but reemerged in the subsequent three weeks

971 ^c Number of isolates that were not present the week prior to the event but emerged in the
 972 subsequent three weeks

973 ^d Number of new isolates that were antimicrobial resistant organisms (AROs)

974 ^e Number of new ARO acquisitions divided by total number of new acquisitions

975 ^f Net impact of the event on the number of isolates detected in the participants weekly urine
 976 samples

977 NA, Not applicable

978 **Figure Legend**

979

980 **Figure 1. Epidemiology and dynamics of catheter-associated bacteriuria.** The complete
981 longitudinal data for four study participants (letters) at each study visit (numbers, starting with 0
982 for baseline) are presented. The first row of pie charts displays the bacterial species that were
983 identified by standard culture methods at each visit, the second row displays the urinalysis test
984 strip results, and the third row displays the potential signs and symptoms of infection that were
985 present at each study visit. White circles with black outlines indicate study visits at which
986 assessments were negative, while empty spaces indicate study visits at which a particular
987 assessment could not be made. [] indicates a caregiver-diagnosed CAUTI, * indicates
988 antimicrobial use, and ^ indicates when the participant's catheter was changed.

989

990 **Figure 2. Impact of catheter changes and antibiotic use on colonization density.** The total
991 number of unique bacterial species isolated from each weekly urine sample (0-10) are displayed
992 for all study participants (A-S) across each study visit (0-30). Symbol color indicates whether an
993 event occurred since the prior visit that could impact colonization density; catheter change
994 (orange), antibiotic use (light blue), or catheter change plus antibiotic use (teal).




Figure 1. Epidemiology and dynamics of catheter-associated bacteriuria. The complete longitudinal data for four study participants (letters) at each study visit (numbers, starting with 0 for baseline) are presented. The first row of pie charts displays the bacterial species that were identified by standard culture methods at each visit, the second row displays the urinalysis test strip results, and the third row displays the potential signs and symptoms of infection that were present at each study visit. White circles with black outlines indicate study visits at which assessments were negative, while empty spaces indicate study visits at which a particular assessment could not be made. [] indicates a caregiver-diagnosed CAUTI, * indicates antimicrobial use, and ^ indicates when the participant's catheter was changed.




Figure 2. Impact of catheter changes and antibiotic use on colonization density. The total number of unique bacterial species isolated from each weekly urine sample (0-10) are displayed for all study participants (A-S) across each study visit (0-30). Symbol color indicates whether an event occurred since the prior visit that could impact colonization density; catheter change (orange), antibiotic use (light blue), or catheter change plus antibiotic use (teal).